undamentalytics Newsletter
Sign in

Vir Biotechnology, Inc. (VIR) stock

Add to watchlist

Add holding +

NASDAQ: VIR Nasdaq Biotechnology Next results ~November 4, 2026

B Fundamentals grade

Vir Biotechnology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$3.2

Revenue-to-maturity model

Base case. Range ~$2.5–$4.1. Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Vir Biotechnology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 35 sales by directors and officers, last 12 monthsInsider trades
  • Funds121 adding, 120 cuttingOf 44 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Vir Biotechnology files

Where Vir Biotechnology stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $303m, up 1495.9% on a year earlier, faster than the 214.0% growth a quarter earlier. That growth ranks 6 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -67.1% from -2454.6% a year earlier. Operating margin widened to -92.4% from -3191.7%. The diluted share count is up 8.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $9.66 a share, against a share price of $11.78.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Vir Biotechnology, Inc.'s trailing-twelve-month revenue grew 1495.9% year on year, with a free-cash-flow margin of -67.1%. Where it stands out: change in growth rate of +1282.0pp ranks 5 of 172 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 1495.9% (+1282.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 1495.9% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 1282.0 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 3099.3 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Loss-making. Operating margin is -92.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -67.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 15.5% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 8.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 64% and a beta of 1.8 against the S&P 500.
  • Gross margin slipping. Gross margin is down 2.7 points on a year ago.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.47 against an average estimate of $0.90: missed by 47.5%
Revenue
$239m, up 19582.5% on a year earlier
Share reaction
-4.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.73

Vir Biotechnology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.7%
  • 1 week-0.4%
  • 1 month-1.5%
  • This year+82.4%
  • 1 year+84.6%
  • 5 years-70.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$303M
Operating margin
-92.4%
Net margin
-83.0%
EPS (TTM, diluted)
$-1.69

Growth

Revenue growth
+1495.9%
Change in growth rate
+1282.0 pts
Share count change
+8.2%

Cash

Free cash flow (TTM)
-$204M
FCF margin
-67.1%
Stock pay % of revenue
15.5%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Share issue
  3. Announcement
  4. Leadership
  5. Results
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Vir Biotechnology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Vir Biotechnology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.02 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.1 ~$2.0–$2.2 Left out: out of range vs price (0.19x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.4 ~$1.4–$5.3 Left out: out of range vs price (0.13x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$3.2 ~$2.5–$4.1 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.2 ~$2.5–$4.1 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Vir Biotechnology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$12.57$26.78$41.87$25.31$10.06$7.34$6.03$11.00
Market value$1.5bn$3.2bn$5.6bn$3.4bn$1.3bn$1.0bn$835m$1.6bn
+ Net debt (− = net cash)−$109m−$437m−$348m−$849m−$242m−$223m−$232m−$279m
Enterprise value$1.4bn$2.8bn$5.2bn$2.6bn$1.1bn$777m$603m$1.4bn
Multiples
Price / sales 188.7x41.8x5.1x2.1x15.7x13.5x12.2x5.4x
Price / earnings ——10.6x6.6x————
Price / free cash flow ———2.1x————
EV / EBITDA ——12.3x3.1x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Vir Biotechnology's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -28.1% of total assets over 7 years.

  • Pricing power 19 / 20

    Gross margin has been a median 96.1%, moving by 3.0 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -221.8%; its worst year was -3191.7%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -83.5% of revenue.

  • Discipline 2 / 20

    The diluted share count rose 15.5% over five years; stock-based pay has been a median 25.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $1m and EPS of −$0.73 (range −$0.95 to −$0.58) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.76 +45% $239m +249%
Next −$2.49 −42% $76m −68%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +27.8% on 90 days ago. In the last 30 days, 0 analysts raised Vir Biotechnology, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Vir Biotechnology, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.37 Current fiscal year, 60 days ago: −$1.78 Current fiscal year, 30 days ago: −$1.76 Current fiscal year, 7 days ago: −$1.76 Current fiscal year, Now: −$1.76 −$1.76 Next fiscal year, 90 days ago: −$2.32 Next fiscal year, 60 days ago: −$2.49 Next fiscal year, 30 days ago: −$2.49 Next fiscal year, 7 days ago: −$2.49 Next fiscal year, Now: −$2.49 −$2.49

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.37−$2.32
60 days ago −$1.78−$2.49
30 days ago −$1.76−$2.49
7 days ago −$1.76−$2.49
Now −$1.76−$2.49

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.90 $0.47 −47.5%
Mar 2026 $0.48 −$0.85 −276.6%
Dec 2025 −$0.45 −$0.31 +31.6%
Sept 2025 −$0.86 −$1.17 −36.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy10100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20263710
  2. Sep 20263710
  3. Aug 20263710
  4. Jul 20263710

Counts of recommendations published by analysts covering Vir Biotechnology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.7%
of tradable shares
Days to cover
7.15
at average volume
Short interest, 1 month
−17%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
6.6%
of shares
Employees
367
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +84.6%

$5.96 on October 31, 2025 to $11.00

ThenNowEffect
Revenue (last 12 months) $19m $303m +1495.9%
P/S multiple 43.1x 5.4x −87.5%
Share count 137m 149m −7.6%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +25.6%

$8.76 on November 3, 2023 to $11.00

ThenNowEffect
Revenue (last 12 months) $491m $303m −38.2%
P/S multiple 2.4x 5.4x +123.7%
Share count 135m 149m −9.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VIR+56%−40%−60%−27%−18%+82%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VIR33%42%50%33%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VIR−63%−56%−75%−47%−66%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 11, 2019: 95% from January 27, 2021 to August 11, 2025. Getting back needed a 1841% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.12 – $11.93
From 52-week high
−7.8%
vs 50-day average
+0.3%
vs 200-day average
+15.2%
Volatility (1 year)
64%
Beta vs S&P 500
1.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.8%
After a week
6 up, 6 down
typical move ±12.4%
After a month
7 up, 5 down
typical move ±15.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −4.4% −0.4% −2.3% +24.9%
May 6, 2026 −7.4% +1.1% −6.8% −13.6%
February 23, 2026 +25.5% −0.3% +23.5% +13.4%
January 12, 2026 +7.9% 0.0% +2.6% +26.8%
November 5, 2025 −2.5% −0.7% +8.8% +23.8%
August 6, 2025 −14.9% +0.7% −10.6% +3.1%
May 7, 2025 −3.9% +1.1% −20.1% −3.2%
February 26, 2025 −10.9% −1.5% −9.7% −26.7%
October 31, 2024 +21.8% −1.5% +28.6% +7.2%
August 1, 2024 −9.4% −3.3% −15.2% −18.7%
May 2, 2024 +18.9% +2.2% +9.4% +21.6%
February 22, 2024 +14.0% +2.1% +11.2% −0.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Vir Biotechnology, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Vir Biotechnology, Inc.
$0 $100M $200M $300M $400M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $118.8M Revenue (TTM), FY23 Q4: $86.2M Revenue (TTM), FY24 Q1: $79.6M Revenue (TTM), FY24 Q2: $78.9M Revenue (TTM), FY24 Q3: $78.6M Revenue (TTM), FY24 Q4: $74.2M Revenue (TTM), FY25 Q1: $20.9M Revenue (TTM), FY25 Q2: $19M Revenue (TTM), FY25 Q3: $16.9M Revenue (TTM), FY25 Q4: $68.6M Revenue (TTM), FY26 Q1: $65.5M Revenue (TTM), FY26 Q2: $303.2M $303.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $118.8M
FY23 Q4 $86.2M
FY24 Q1 $79.6M
FY24 Q2 $78.9M
FY24 Q3 $78.6M
FY24 Q4 $74.2M
FY25 Q1 $20.9M
FY25 Q2 $19M
FY25 Q3 $16.9M
FY25 Q4 $68.6M
FY26 Q1 $65.5M
FY26 Q2 $303.2M
Revenue growth, TTM YoY Vir Biotechnology, Inc.
-500% 0% 500% 1000% 1500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -95.0% Revenue growth, TTM YoY, FY23 Q4: -94.7% Revenue growth, TTM YoY, FY24 Q1: -82.2% Revenue growth, TTM YoY, FY24 Q2: -83.9% Revenue growth, TTM YoY, FY24 Q3: -33.8% Revenue growth, TTM YoY, FY24 Q4: -13.9% Revenue growth, TTM YoY, FY25 Q1: -73.8% Revenue growth, TTM YoY, FY25 Q2: -75.9% Revenue growth, TTM YoY, FY25 Q3: -78.6% Revenue growth, TTM YoY, FY25 Q4: -7.6% Revenue growth, TTM YoY, FY26 Q1: 214.0% Revenue growth, TTM YoY, FY26 Q2: 1495.9% 1495.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -95.0%
FY23 Q4 -94.7%
FY24 Q1 -82.2%
FY24 Q2 -83.9%
FY24 Q3 -33.8%
FY24 Q4 -13.9%
FY25 Q1 -73.8%
FY25 Q2 -75.9%
FY25 Q3 -78.6%
FY25 Q4 -7.6%
FY26 Q1 214.0%
FY26 Q2 1495.9%
Operating margin (TTM) Vir Biotechnology, Inc.
-4000% -3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -585.7% Operating margin (TTM), FY23 Q4: -794.0% Operating margin (TTM), FY24 Q1: -780.2% Operating margin (TTM), FY24 Q2: -715.6% Operating margin (TTM), FY24 Q3: -774.7% Operating margin (TTM), FY24 Q4: -791.3% Operating margin (TTM), FY25 Q1: -3099.7% Operating margin (TTM), FY25 Q2: -3191.7% Operating margin (TTM), FY25 Q3: -3253.6% Operating margin (TTM), FY25 Q4: -699.2% Operating margin (TTM), FY26 Q1: -720.8% Operating margin (TTM), FY26 Q2: -92.4% -92.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -585.7%
FY23 Q4 -794.0%
FY24 Q1 -780.2%
FY24 Q2 -715.6%
FY24 Q3 -774.7%
FY24 Q4 -791.3%
FY25 Q1 -3099.7%
FY25 Q2 -3191.7%
FY25 Q3 -3253.6%
FY25 Q4 -699.2%
FY26 Q1 -720.8%
FY26 Q2 -92.4%
FCF margin (TTM) Vir Biotechnology, Inc.
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -562.6% FCF margin (TTM), FY23 Q4: -928.7% FCF margin (TTM), FY24 Q1: -978.6% FCF margin (TTM), FY24 Q2: -581.6% FCF margin (TTM), FY24 Q3: -602.3% FCF margin (TTM), FY24 Q4: -611.4% FCF margin (TTM), FY25 Q1: -2023.6% FCF margin (TTM), FY25 Q2: -2454.6% FCF margin (TTM), FY25 Q3: -2728.5% FCF margin (TTM), FY25 Q4: -578.5% FCF margin (TTM), FY26 Q1: -686.5% FCF margin (TTM), FY26 Q2: -67.1% -67.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -562.6%
FY23 Q4 -928.7%
FY24 Q1 -978.6%
FY24 Q2 -581.6%
FY24 Q3 -602.3%
FY24 Q4 -611.4%
FY25 Q1 -2023.6%
FY25 Q2 -2454.6%
FY25 Q3 -2728.5%
FY25 Q4 -578.5%
FY26 Q1 -686.5%
FY26 Q2 -67.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 3 11 8 76 1,095 1,616 86 74 69 303
Gross profit — — 8 76 1,030 1,469 83 73 69 —
EBITDA −81 −117 −175 −293 426 840 −665 −573 −468 −269
Operating income −81 −119 −178 −297 421 833 −684 −587 −479 −280
Net income −70 −116 −175 −299 529 516 −615 −522 −438 −252
Diluted EPS −$2.03 −$0.94 −$1.44 −$2.51 $3.96 $3.83 −$4.59 −$3.83 −$3.16 −$1.69
Growth (year on year)
Revenue — +293.9% −24.2% +843.9% +>999% +47.5% −94.7% −13.9% −7.6% +>999%
EBITDA — — — — — +97.1% −179.2% — — —
Operating income — — — — — +98.0% −182.1% — — —
Net income — — — — — −2.4% −219.2% — — —
Diluted EPS — — — — — −3.3% −219.8% — — —
Margins
Gross margin — — 100.0% 100.0% 94.0% 90.9% 96.8% 98.9% 100.0% —
EBITDA margin <−999% <−999% <−999% −383.1% 38.9% 52.0% −771.5% −771.7% −682.1% −88.7%
Operating margin <−999% <−999% <−999% −388.9% 38.4% 51.6% −794.0% −791.3% −699.2% −92.4%
Net margin <−999% <−999% <−999% −391.1% 48.3% 31.9% −713.7% −703.4% −638.9% −83.0%
Free-cash-flow margin <−999% −958.8% <−999% −258.6% −6.3% 98.7% −928.7% −611.4% −578.5% −67.1%
Cash flow
Cash from operations −66 −94 −130 −191 −48 1,663 −779 −446 −392 −203
Capital spending 3 8 9 7 22 68 22 7 5 1
Free cash flow −69 −102 −139 −197 −69 1,595 −800 −454 −397 −204
Stock-based pay 5 5 9 28 84 102 111 78 49 47
Free cash flow after stock pay −74 −107 −147 −225 −153 1,493 −912 −532 −446 −251
Balance sheet
Cash 188 48 109 437 348 849 242 223 232 279
Total debt 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −188 −48 −109 −437 −348 −849 −242 −223 −232 −279
Diluted shares 34m 123m 121m 119m 133m 135m 134m 136m 139m 149m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.2bn
Short-term assets $574mLonger-term assets $641m
What it owes, and who funded it · $1.2bn
Short-term liabilities $95mLonger-term liabilities $137mShareholders' equity $982m
  • Short-term assets cover short-term liabilities $574m of assets due within a year against $95m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $574m short-term assets against $137m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Vir Biotechnology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+8.2%
year over year
R&D spending
159.6%
of revenue
Sales & admin spending
32.8%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated VIR VCEL ADPT ARVN SNDX IOVA Median
Revenue, last 12 months $303m $306m $308m $317m $290m $325m $56m
Revenue growth, last 12 months >999% 23.0% 50.1% −15.0% 159.7% 34.5% 12.6%
Revenue growth, 3-year average −14.8% 19.8% 17.6% 26.1% 177.8% — 13.7%
Revenue growth, latest quarter >999% 22.5% 21.5% >999% 81.6% 65.7% 10.2%
Gross margin 96.1% 74.6% 75.6% — — 48.4% 82.9%
Operating margin −92.4% 6.0% −12.2% −5.7% −61.7% −92.7% −189.4%
Operating margin, 3-year average <−999% 1.6% −66.8% −145.1% −781.5% −554.7% −363.5%
Net margin −83.0% 7.9% −20.7% 2.9% −72.3% −89.1% −169.8%
Cash from operations / revenue −66.8% 22.7% −6.8% −65.4% −61.2% −81.3% −168.0%
Free-cash-flow margin −67.1% 20.1% −7.8% −65.9% −61.2% −91.2% −162.4%
Free-cash-flow margin, 3-year average <−999% 5.3% −43.0% −135.2% −652.6% −482.4% −310.0%
Stock pay / revenue 15.5% 12.2% 15.9% 11.6% 18.2% 14.4% 20.0%
Change in share count 8.2% 0.6% 4.1% −7.6% 2.5% 29.6% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 1495.9% 12.6% 8 of 172
Change in growth rate Growth +1282.0pp -0.1pp 5 of 172
Gross margin Profitability 96.1% 82.4% 12 of 75
Operating margin Profitability -92.4% -189.4% 73 of 175
Net margin Profitability -83.0% -157.3% 76 of 180
Free-cash-flow margin Cash generation -67.1% -145.4% 72 of 176
Stock pay as % of revenue Cash generation 15.5% 19.2% 78 of 179
Change in share count Balance sheet 8.2% 7.9% 82 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License and Collaboration Revenue $63.1M 93.6% ▲ 2.9%
Other Revenue $3.4M 5.0% ▲ 44.7%
Grant $2M 3.0% ▼ 80.6%
Profit Sharing Amount Constrained $0 0.0% —
Profit Sharing Amount Previously Constrained Released $0 0.0% —
Profit Sharing Amount -$1.1M -1.7% ▼ 112.5%

From Vir Biotechnology, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.5B
Institutions reporting
235
Shares held vs prior quarter
▲ 4.6%
Positions opened / closed
29 / 43

Top buyers and sellers, Q2 2026: 121 institutions bought and 120 sold ; the biggest buyer was Point72 Asset Management, L.P (+3.7M shares) and the biggest seller Jacobs Levy Equity Management, Inc (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $211M 20.7M 14.1% ▲ 14.9%
Arch Venture Management, LLC $129M 12.7M 8.7% ▼ 1.7%
Vanguard Portfolio Management LLC $117M 11.5M 7.8% ▲ 24.7%
Sb Investment Advisers (UK) Ltd $112M 10.9M 7.5% 0.0%
State Street Corp $102M 10.0M 6.8% ▲ 39.5%
Gsk PLC $87.1M 8.6M 5.8% 0.0%
Vanguard Capital Management LLC $65.1M 6.4M 4.4% ▲ 18.7%
Point72 Asset Management, L.P. $57.7M 5.7M 3.9% ▲ 190.3%
Geode Capital Management, LLC $34.1M 3.3M 2.3% ▲ 26.0%
Dimensional Fund Advisors LP $31.8M 3.1M 2.1% ▲ 20.9%
ADAR1 Capital Management, LLC $25M 2.5M 1.7% ▼ 10.5%
Goldman Sachs Group Inc $24.1M 2.4M 1.6% ▼ 27.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vir Biotechnology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8.3M 35 trades by 9 insiders · 100% under pre-set plans
Net ▼ $8.3M net selling
Insider Date Trade Shares Price Value
Sabatini Brent SVP, Chief Accounting Officer June 1, 2026 Sell pre-set plan 379 $9.45 $3,582
Napolitano Janet Director June 1, 2026 Sell pre-set plan 3,200 $9.45 $30,240
Sato Vicki L Director May 1, 2026 Sell pre-set plan 22,000 $10.05 $221,100
De Backer Marianne President and CEO April 6, 2026 Sell pre-set plan 72,559 $9.16 $664,640
Sato Vicki L Director April 1, 2026 Sell pre-set plan 22,000 $9.07 $199,540
Sabatini Brent SVP, Chief Accounting Officer March 23, 2026 Sell pre-set plan 7,711 $9.12 $70,324
Sato Vicki L Director March 2, 2026 Sell pre-set plan 21,800 $9.50 $207,100
Sato Vicki L Director March 2, 2026 Sell pre-set plan 200 $9.98 $1,996
De Verneuil Vanina EVP, General Counsel, Corp Sec February 25, 2026 Sell pre-set plan 13,700 $9.82 $134,534
Eisner Mark EVP and Chief Medical Officer February 25, 2026 Sell pre-set plan 1,889 $9.82 $18,550
De Backer Marianne Chief Executive Officer February 24, 2026 Sell pre-set plan 14,762 $9.53 $140,682
De Verneuil Vanina EVP, General Counsel, Corp Sec February 24, 2026 Sell pre-set plan 3,117 $9.53 $29,705

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 23, 2026
  • January 12, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Vir Biotechnology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Vir Biotechnology, Inc. in brief

What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Vir Biotechnology, Inc.'s stock ticker?
Vir Biotechnology, Inc. trades under the ticker VIR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Vir Biotechnology, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Vir Biotechnology, Inc. reported revenue of $303M, 1495.9% higher than a year earlier, according to its SEC filings.
What is Vir Biotechnology, Inc.'s free cash flow?
Vir Biotechnology, Inc.'s free-cash-flow margin is -67.1% of revenue over the trailing twelve months, ranking 72 of the 176 biotechnology companies we cover.
Who are Vir Biotechnology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Arch Venture Management, LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Vir Biotechnology, Inc.'s market cap?
On November 2, 2026, Vir Biotechnology, Inc.'s market capitalisation was about $1.6B and net debt of -$279M. Market figures come from third-party market data and may be delayed.
Who are Vir Biotechnology, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Vir Biotechnology, Inc. are Vericel Corp, Adaptive Biotechnologies Corp, Arvinas, Inc., Syndax Pharmaceuticals Inc and Iovance Biotherapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Vir Biotechnology, Inc.'s.
Are insiders buying or selling Vir Biotechnology, Inc. stock?
Over the last 12 months, Vir Biotechnology, Inc.'s directors and officers reported 0 open-market purchases and 35 sales on Form 4. The insider trading page charts every trade.
When is Vir Biotechnology, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Vir Biotechnology, Inc. announces its own schedule.